Cancer-Associated Venous Thromboembolism: Anticoagulation Considerations and Controversies (On-Demand)
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 90 Minutes
Overview
This presentation will include a thorough review of the literature and remaining controversies in terms of anticoagulation for cancer-associated venous thromboembolism (VTE), from historical data of warfarin versus low molecular weight heparin to more recent landmark direct oral anticoagulants trials. This data will be supplemented by a discussion on pharmacologic properties and clinical pearls of anticoagulants, in addition to considerations for special populations. Ultimately, the presentation will discuss how to apply the literature to select the optimal anticoagulant for cancer-associated VTE, considering both patient and disease-specific characteristics.
Learning Objectives:
- Identify current guidelines and challenges related to anticoagulation in patients with cancer
- Describe the pharmacologic properties of direct oral anticoagulants (DOACs), low molecular weight heparin (LMWH), and warfarin
- Discuss limitations with the landmark trials for DOACs in cancer-associated venous thromboembolism (VTE)
- Recognize disease- and patient-specific characteristics that inform the selection of the optimal anticoagulant in patients with cancer-associated VTE
Target Audience:
This activity is intended for oncology nurse practitioners, physician assistants, nurses, and other healthcare providers involved in the care of cancer patients.
Evenings in Onboarding is supported in part by independent medical educational grants from Novocure, Inc., Merck Sharp & Dohme Corp., and Bristol Myers Squibb Company.
Presented By
Faculty
Claressa Rosacina, MSN, RN, AGPCNP-BC (Moderator)
Claressa Rosacina is the lead Nurse Practitioner at Oncology Consultants and also serves as their Clinical Support Manager. She leads large teams of APPs and Medical Scribes. She practices closely with the Vice President of the company, Dr. Alex Nguyen. She originally volunteered at MD Anderson Cancer Hospital’s ER and found her calling through working with cancer patients. She then pursued her passion and obtained both her Bachelor and Master of Science in Nursing with a subspecialty in Adult-Gerontology through Texas Woman’s University.
Claressa first started working at MD Anderson Cancer Hopital as an ICU nurse for five years, then transitioned to Oncology Consultants in 2014 as a Nurse Practitioner. She has served as the lead APP and Clinical Support Manager in 2021, making sure all new APPs and Medical Scribes are well trained in their roles. Her key interests are breast cancer, colon cancer, lymphoma, and leukemia.She is also passionate about cancer prevention and works very closely with teams in creating a Survivorship Clinic at Oncology Consultants. Claressa is an active member of ONS (Oncology Nursing Society) and a member of Sigma Theta Tau, the International Honor Society of Nursing. Claressa and her husband Raymond Donato share three beautiful children and reside in Houston, TX. She enjoys gardening, dancing, and traveling in her spare time.
Madeleine Ochs, PharmD, BCOP (Speaker)
Madeleine Ochs graduated with her PharmD from Purdue University, after which she completed a PGY1 Pharmacy Practice Residency and PGY2 Hematology/Oncology Pharmacy Residency, both at Michigan Medicine. She currently works as a clinical pharmacist specialist in hematology at Michigan Medicine. In her clinical practice, she primarily takes care of patients with benign and malignant hematologic conditions.
Madeleine Ochs, PharmD, BCOP discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.
Claressa Rosacina, MSN, RN, AGPCNP-BC discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.
Available Credit
- 1.25 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.25 credit.
Price
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test and score a minimum of 70%
- Submit the evaluation form
DISCLAIMER:
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above